you are viewing a single comment's thread.
I would feel more confident for the long term if SNTA didn't launch Galaxy phase III until the final data from the phase II trial is in and analyzed.
It's somewhat odd that they will transition into phase 3 (soon!) before phase 2 is finished, technically. However, one must assume that they know the results/beneficial subgroups of phase 2 by now.
**Of note: also watch for results of INFI for their hsp90 inhibitor for NSCLC later this year.